Carmen Fotino

Carmen Fotino

Auto-generated profile, based on publicly available information

Carmen Fotino

Cell Transplant Center, Diabetes Research Institute, University of Miami, Miami, FL

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
Fulvio CelsiFulvio Celsi
Fulvio Celsi
Paola PizzoPaola Pizzo
Paola Pizzo
MBMarisa Brini
Marisa Brini
SLSara Leo
Sara Leo
CFCarmen Fotino
Carmen Fotino
RRRosario Rizzuto
Rosario Rizzuto

1 March 2007 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
Laura PucciLaura Pucci
Laura Pucci
STStefano Triscornia
Stefano Triscornia
DLDaniela Lucchesi
Daniela Lucchesi
CFCarmen Fotino
Carmen Fotino
GPGiovanni Pellegrini
Giovanni Pellegrini
GPGiuseppe Penno
Giuseppe Penno
Background: Early identification of impairment in renal function is crucial in diabetic patients. Serum cystatin C may be the most sensitive indicator of glomerular filtration rate (GFR) in the clinical setting.

25 February 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
DBDora M. Berman
Dora M. Berman
RMR. Damaris Molano
R. Damaris Molano
CFCarmen Fotino
Carmen Fotino
UUUlisse Ulissi
Ulisse Ulissi
JGJennifer Gimeno
Jennifer Gimeno
APAntonello Pileggi
Antonello Pileggi
Transplantation of pancreatic islets is a therapeutic option to preserve or restore β-cell function. Our study was aimed at developing a clinically applicable protocol for extrahepatic transplantation of pancreatic islets. The potency of islets implanted onto the omentum, using an in situ–generated adherent, resorbable plasma-thrombin biologic scaffold, was evaluated in diabetic rat and nonhuman primate (NHP) models. Intraomental islet engraftment in the biologic scaffold was confirmed by achievement of improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species. Long-term nonfasting normoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats. Intraomental graft recipients displayed lower levels of serum biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and α2-macroglobulin). Importantly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equivalent to that of pure (>95% endocrine) preparations after intraomental biologic scaffold implantation. Moreover, the biologic scaffold sustained allogeneic islet engraftment in immunosuppressed recipients. Collectively, our feasibility/efficacy data, along with the simplicity of the procedure and the safety of the biologic scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II clinical trial.

29 January 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
AVAndrea Vergani
Andrea Vergani
STSara Tezza
Sara Tezza
FDFrancesca D'Addio
Francesca D'Addio
CFCarmen Fotino
Carmen Fotino
KLKaifeng Liu
Kaifeng Liu
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
Background—: Heart transplantation is a lifesaving procedure for patients with end-stage heart failure. Despite much effort and advances in the field, current immunosuppressive regimens are still associated with poor long-term cardiac allograft outcomes, and with the development of complications, including infections and malignancies, as well. The development of a novel, short-term, and effective immunomodulatory protocol will thus be an important achievement. The purine ATP, released during cell damage/activation, is sensed by the ionotropic purinergic receptor P2X7 (P2X7R) on lymphocytes and regulates T-cell activation. Novel clinical-grade P2X7R inhibitors are available, rendering the targeting of P2X7R a potential therapy in cardiac transplantation.Methods and Results—: We analyzed P2X7R expression in patients and mice and P2X7R targeting in murine recipients in the context of cardiac transplantation. Our data demonstrate that P2X7R is specifically upregulated in graft-infiltrating lymphocytes in cardiac-transplanted humans and mice. Short-term P2X7R targeting with periodate-oxidized ATP promotes long-term cardiac transplant survival in 80% of murine recipients of a fully mismatched allograft. Long-term survival of cardiac transplants was associated with reduced T-cell activation, T-helper cell 1/T-helper cell 17 differentiation, and inhibition of STAT3 phosphorylation in T cells, thus leading to a reduced transplant infiltrate and coronaropathy. In vitro genetic upregulation of the P2X7R pathway was also shown to stimulate T-helper cell 1/T-helper cell 17 cell generation. Finally, P2X7R targeting halted the progression of coronaropathy in a murine model of chronic rejection as well.Conclusions—: P2X7R targeting is a novel clinically relevant strategy to prolong cardiac transplant survival.

16 April 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
AVAndrea Vergani
Andrea Vergani
CFCarmen Fotino
Carmen Fotino
FDFrancesca D'Addio
Francesca D'Addio
STSara Tezza
Sara Tezza
MPMichele Podetta
Michele Podetta
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
The lymphocytic ionotropic purinergic P2X receptors (P2X1R-P2X7R, or P2XRs) sense ATP released during cell damage-activation, thus regulating T-cell activation. We aim to define the role of P2XRs during islet allograft rejection and to establish a novel anti-P2XRs strategy to achieve long-term islet allograft function. Our data demonstrate that P2X1R and P2X7R are induced in islet allograft-infiltrating cells, that only P2X7R is increasingly expressed during alloimmune response, and that P2X1R is augmented in both allogeneic and syngeneic transplantation. In vivo short-term P2X7R targeting (using periodate-oxidized ATP [oATP]) delays islet allograft rejection, reduces the frequency of Th1/Th17 cells, and induces hyporesponsiveness toward donor antigens. oATP-treated mice displayed preserved islet grafts with reduced Th1 transcripts. P2X7R targeting and rapamycin synergized in inducing long-term islet function in 80% of transplanted mice and resulted in reshaping of the recipient immune system. In vitro P2X7R targeting using oATP reduced T-cell activation and diminished Th1/Th17 cytokine production. Peripheral blood mononuclear cells obtained from long-term islet-transplanted patients showed an increased percentage of P2X7R+CD4+ T cells compared with controls. The beneficial effects of oATP treatment revealed a role for the purinergic system in islet allograft rejection, and the targeting of P2X7R is a novel strategy to induce long-term islet allograft function.

4 August 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Alessandro RimessiAlessandro Rimessi
Alessandro Rimessi
Saverio MarchiSaverio Marchi
Saverio Marchi
CFCarmen Fotino
Carmen Fotino
ARAnna Romagnoli
Anna Romagnoli
KHKay Huebner
Kay Huebner
RRRosario Rizzuto
Rosario Rizzuto
Despite the growing interest in the Fhit tumor suppressor protein, frequently deleted in human cancers, the mechanism of its powerful proapoptotic activity has remained elusive. We here demonstrate that Fhit sensitizes the low-affinity Ca 2+ transporters of mitochondria, enhancing Ca 2+ uptake into the organelle both in intact and in permabilized cells, and potentiating the effect of apoptotic agents. This effect can be attributed to the fraction of Fhit sorted to mitochondria, as a fully mitochondrial Fhit (a chimeric protein including a mitochondrial targeting sequence) retains the Ca 2+ signaling properties of Fhit and the proapoptotic activity of the native protein (whereas the effects on the cell cycle are lost). Thus, the partial sorting of Fhit to mitochondria allows to finely tune the sensitivity of the organelle to the highly pleiomorphic Ca 2+ signals, synergizing with apoptotic challenges. This concept, and the identification of the molecular machinery, may provide ways to act on apoptotic cell death and its derangement in cancer.